Toggle light / dark theme

“We have found a key to controlling the switching on and off of proteins by combining photochemistry and hydrolysis,” says KTH researcher Tove Kivijärvi.

When designing materials that aim to improve medicine, you need to be able to control the functions of the material in a very precise way. If this is achieved, cell environments similar to the human body can be created in the lab, which is important for understanding biological mechanisms, disease processes and how the body repairs itself. Biological materials can also be used to study how drugs work and to streamline drug testing and preclinical studies.

Contact: Cara Martinez | Email: [email protected]

Los Angeles — April 14, 2015 – An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai. Currently, there is no treatment that slows the progression of the disease, which is the leading cause of vision loss in people over 65.

“This is the first study to show preservation of vision after a single injection of induced neural progenitor stem cells into a AMD-like rat model for retinal degeneration,” said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.

Glioblastoma (GBM) is a highly aggressive and malignant brain tumor with a poor prognosis. Treatment options are limited, and the development of effective therapeutics is a major challenge. Here are some current and emerging therapeutic strategies for GBM:

Current Therapies 1. Surgery: Surgical resection is the primary treatment for GBM, aiming to remove as much of the tumor as possible. 2. Radiation Therapy: Radiation therapy is used to kill remaining tumor cells after surgery. 3. Temozolomide (TMZ): TMZ is a chemotherapy drug that is used to treat GBM, often in combination with radiation therapy. 4. Bevacizumab (Avastin): Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) to inhibit angiogenesis.

Emerging Therapies 1. Immunotherapy: Immunotherapies, such as checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) and cancer vaccines, aim to stimulate the immune system to attack GBM cells. 2. Targeted Therapies: Targeted therapies focus on specific molecular pathways involved in GBM, such as the PI3K/AKT/mTOR pathway. 3. Gene Therapy: Gene therapies aim to introduce genes that can help kill GBM cells or inhibit tumor growth. 4. Oncolytic Viruses: Oncolytic viruses are engineered to selectively infect and kill GBM cells. 5. CAR-T Cell Therapy: CAR-T cell therapy involves genetically modifying T cells to recognize and attack GBM cells. 6. Small Molecule Inhibitors: Small molecule inhibitors target specific proteins involved in GBM, such as EGFR, PDGFR, and BRAF.

Organelles in cells were originally often independent cells, which were incorporated by host cells and lost their independence in the course of evolution. A team of biologists headed by Professor Dr. Eva Nowack at Heinrich Heine University Düsseldorf (HHU) are examining the way in which this assimilation process occurs and how quickly. They now describe their findings about an intermediate stage in this process in Science Advances.

Eukaryotic cells contain a large number of functional sub-units, so-called organelles. They perform important functions within the cell. Some organelles were independent, at some point in the past. They were then taken up by a cell and have evolved over time in symbiosis with the .

These “endosymbionts” lost their ability to function autonomously in the process. One well-known example of this type of is the mitochondrion, which evolved from a bacterium.